Your browser doesn't support javascript.
loading
Profiling of Natural Killer Interactions With Cancer Cells Using Mass Cytometry.
Hallisey, Margaret; Dennis, Jenna; Gabriel, Elizabeth P; Masciarelli, Alyssa; Chen, Jiajia; Abrecht, Charlotte; Brainard, Martha; Marcotte, William M; Dong, Han; Hathaway, Emma; Tarannum, Mubin; Vergara, Juliana A; Schork, Abigail N; Tyan, Kevin; Tarantino, Giuseppe; Liu, David; Romee, Rizwan; Rahma, Osama E; Severgnini, Mariano; Hodi, F Stephen; Baginska, Joanna.
Afiliação
  • Hallisey M; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Dennis J; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Gabriel EP; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Masciarelli A; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Chen J; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Abrecht C; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Brainard M; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Marcotte WM; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Dong H; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Hathaway E; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Tarannum M; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Vergara JA; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Schork AN; Longwood Medical Area CyTOF Core, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Tyan K; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
  • Tarantino G; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Liu D; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Romee R; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Rahma OE; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
  • Severgnini M; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Hodi FS; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Baginska J; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address: joanna_baginska@dfci.harvard.edu.
Lab Invest ; 103(8): 100174, 2023 08.
Article em En | MEDLINE | ID: mdl-37169083
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Citotoxicidade Imunológica / Neoplasias Idioma: En Revista: Lab Invest Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Citotoxicidade Imunológica / Neoplasias Idioma: En Revista: Lab Invest Ano de publicação: 2023 Tipo de documento: Article